Tonix Pharmaceuticals (NASDAQ:TNXP) Director Carolyn Taylor Purchases 1,415 Shares

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Director Carolyn Taylor acquired 1,415 shares of the firm’s stock in a transaction on Friday, June 12th. The shares were bought at an average price of $10.55 per share, for a total transaction of $14,928.25. Following the completion of the transaction, the director owned 1,833 shares of the company’s stock, valued at approximately $19,338.15. This trade represents a 338.52% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Tonix Pharmaceuticals Stock Performance

Shares of Tonix Pharmaceuticals stock opened at $11.35 on Monday. The stock has a market cap of $180.92 million, a price-to-earnings ratio of -0.79 and a beta of 1.67. The stock has a 50 day moving average price of $13.04 and a 200-day moving average price of $14.93. Tonix Pharmaceuticals Holding Corp. has a one year low of $10.03 and a one year high of $69.97.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings results on Monday, May 11th. The company reported ($2.93) earnings per share for the quarter, missing the consensus estimate of ($2.54) by ($0.39). The company had revenue of $6.88 million for the quarter, compared to analysts’ expectations of $6.13 million. Tonix Pharmaceuticals had a negative net margin of 839.52% and a negative return on equity of 67.65%. Sell-side analysts predict that Tonix Pharmaceuticals Holding Corp. will post -9.94 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on TNXP. Wall Street Zen lowered shares of Tonix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, April 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research report on Monday, April 20th. Finally, TD Cowen raised shares of Tonix Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, May 5th. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $22.00.

Institutional Trading of Tonix Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Royal Bank of Canada purchased a new stake in shares of Tonix Pharmaceuticals during the first quarter valued at $610,000. Geode Capital Management LLC increased its stake in Tonix Pharmaceuticals by 182.4% in the 2nd quarter. Geode Capital Management LLC now owns 175,212 shares of the company’s stock worth $6,305,000 after buying an additional 113,175 shares during the period. JPMorgan Chase & Co. bought a new stake in Tonix Pharmaceuticals during the 2nd quarter valued at about $129,000. Legal & General Group Plc bought a new stake in Tonix Pharmaceuticals during the 2nd quarter valued at about $25,000. Finally, New York State Common Retirement Fund purchased a new stake in Tonix Pharmaceuticals in the 2nd quarter valued at about $104,000. 82.26% of the stock is currently owned by institutional investors.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.